Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -1.50 -2.38% 61.50 24,146 08:00:00
Bid Price Offer Price High Price Low Price Open Price
60.00 63.00 61.50 61.50 61.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -5.52 -10.70 27
Last Trade Time Trade Type Trade Size Trade Price Currency
16:03:52 O 1,000 60.95 GBX

Destiny Pharma (DEST) Latest News

More Destiny Pharma News
Destiny Pharma Takeover Rumours

Destiny Pharma (DEST) Discussions and Chat

Destiny Pharma Forums and Chat

Date Time Title Posts
17/9/202018:02Destiny Pharma plc193

Add a New Thread

Destiny Pharma (DEST) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Destiny Pharma trades in real-time

Destiny Pharma (DEST) Top Chat Posts

Destiny Pharma Daily Update: Destiny Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DEST. The last closing price for Destiny Pharma was 63p.
Destiny Pharma Plc has a 4 week average price of 48.50p and a 12 week average price of 30p.
The 1 year high share price is 63p while the 1 year low share price is currently 30p.
There are currently 43,815,195 shares in issue and the average daily traded volume is 139,238 shares. The market capitalisation of Destiny Pharma Plc is £26,946,344.93.
hedgehog 100: Interesting to compare DEST to recent trebler SCLP at the moment: DEST: 57p, market cap. £25M. SCLP: 15.875p, market cap. £99.87M. 07/09/2020 07:00 UK Regulatory (RNS & others) Destiny Pharma PLC Collaboration to co-develop treatment for COVID-19 "... Destiny Pharma and SporeGen are also very pleased to announce that IUK has awarded a grant of GBP800,000 to fund the majority of the GBP1 million cost of the initial SPOR-COV programme. ..." 27/08/2020 07:00 UK Regulatory (RNS & others) Scancell Holdings Plc Funds awarded by Innovate UK for COVID-19 vaccine "... With Scancell set to receive approximately GBP2m of the consortium awarded funding, the Company expects it to cover the majority of the development and Phase 1 trial costs. ..."
hedgehog 100: 10/09/2020 07:00 UKREG Destiny Pharma PLC Notice of Results Notice of Interim Results Brighton, United Kingdom - 10 September 2020 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), will announce its financial results for the six months ended 30 June 2020 on Thursday, 17 September 2020. A webcast for analysts will take place at 09:30am BST. P.S. Thanks Supracat.
hedgehog 100: Of course, it isn't only a future pandemic that DEST can help with, but the current COVID-19 pandemic as well: 29/04/2020 07:00 UK Regulatory (RNS & others) Destiny Pharma PLC Final Results " ... Neil Clark, Chief Executive Officer of Destiny Pharma, commented: ... "It has been widely reported that the treatment of many patients infected with COVID-19 has been significantly complicated by secondary bacterial infections that take hold and contribute to the mortality rate. This highlights yet again the need for new, safe and effective antimicrobial drugs. We continue to believe that our proprietary XF-platform is well-positioned to generate such products and remain very positive about the future of Destiny Pharma." ... "
hedgehog 100: DEST is forecasting peak US sales for its XF-73 drug of $US 1 billion. In contrast, DEST's current market cap. at 45.1p is just £19.78 million. 03/03/2020 07:00 UK Regulatory (RNS & others) Destiny Pharma PLC Clinical and Business Update " ... The Company's ongoing Phase 2b clinical trial of its lead asset, XF-73 (exeporfinium chloride) nasal gel, is testing XF-73 as a novel drug for the prevention of post-surgical infections caused by Staphylococcus aureus (SA), including the superbug variant methicillin-resistant S. aureus (MRSA). US, EU and WHO surgical guidelines are recommending this type of treatment to tackle nasal SA/MRSA bacterial carriage in all high risk surgeries and the Company forecast peak US sales of $US 1 billion driven by the appropriate use of XF-73 in millions of eligible surgical procedures. ..."
supracat: Great news and justification for the great work done by Neil and the team getting to this stage. Share price deserves a significant re rating upwards. ?
tarlok: timing is everything....normally you get the "panicked" sells when you see price here...but not one sell fell for it.... (DEST share holders are made of sterner stuff ! ) so MM now move price up....and was looking for the sign to buy ,so now i have increased my position
hedgehog 100: 27/07/2020 07:00 UKREG Destiny Pharma PLC Update on Phase 2b clinical study of XF-73 Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections Protocol amendment agreed with FDA to reduce Phase 2b study size without compromising its statistical power or clinical value Study two thirds enrolled. Recruitment now expected to complete by year end Planned study interim safety review to be announced in August 2020 Brighton, United Kingdom - 27 July 2020 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel treatments for hospital infections that address the global challenge of antimicrobial resistance (AMR), is pleased to announce a clinical protocol amendment has been agreed with FDA for its ongoing phase 2b study of lead asset XF-73. The study is evaluating XF-73, as a nasal gel, for the prevention of post-surgical hospital infections caused by Staphylococcus aureus bacteria, such as MRSA. The agreed amendment recognizes the impact COVID-19 has had in slowing patient recruitment in clinical studies since March and the FDA's willingness to support certain protocol amendments that help to accelerate the completion of ongoing clinical trials but do not compromise a study's integrity and clinical objectives. The amendment to the protocol incorporates a change to the primary patient population where the primary endpoint for the study will be measured. The primary microbiological endpoint post-surgery will now be measured in those patients who had a positive load of nasal Staphylococcus aureus before receiving the study treatment. This contrasts to the original primary population, which included all randomised patients regardless of their baseline nasal load of Staphylococcus aureus. Very importantly, this change enables a reduction in the prospectively defined study size from 200 patients to 125 while maintaining the statistical power of the study and its clinical value. This preserves the potential of the trial results to be a key step towards the Phase 3 clinical trial programme of XF-73. Destiny Pharma has informed all appropriate regulatory bodies and ethics committees involved. Other protocol modifications agreed with the FDA regarding study procedures will also make it easier for hospitals to recruit and retain hospital patients. Destiny Pharma expects that as the incidence of COVID-19 continues to decline in European hospitals they will begin recruiting patients into the study again and that recruitment into US study sites is likely to lag, given the higher infection incidence. That said, the study has already enrolled 77 patients out of the new target of 125 and the Company expects to have over 20 sites open in three countries actively recruiting the remaining patients in the next few months with the majority of these being FDA-compliant sites in Europe. The study remains on track to complete recruitment by the end of 2020. The result of a planned interim safety review by the study's Independent Safety Monitoring Board is expected to be announced in August 2020. Neil Clark, Chief Executive Officer of Destiny Pharma, commented: "We are very pleased to have agreed the protocol amendment with the FDA. The changes will help us complete recruitment later in 2020 and still be well placed to move towards Phase 3 clinical studies if the Phase 2b results are positive. Destiny Pharma is funded through to the last quarter of 2021 and remains confident in the clinical need and significant commercial opportunity for its lead clinical asset XF-73 as a novel preventive treatment of serious hospital infections".
hedgehog 100: "finnCap Research Company Notes - 3 March 2020" "Destiny Pharma (DEST) : Corp" "Share price (p) 35.5 Target price (p) 250.0 Market cap (£m) 15.5 Enterprise value (£m) 6.4" HTTP:// Tole 13 May '20 - 12:45 - 96 of 110 0 2 0 "Surprised by the retrace here. Believe these have plenty potential going forward especially with the covid19 element. Finncap highlighted these opportunities in their most recent note. “On a more positive note, Destiny is looking at several new grant-funded projects or government-funded initiatives that could test the utility of XF-73 as a new COVID-19- related treatment. As evidenced by retrospective studies of COVID-19 patients in Wuhan, China, it is becoming established that secondary bacterial respiratory infections take advantage of immune-compromised COVID-19 intensive care patients and are a significant cause of mortality in the SARS-CoV-2 pandemic. Destiny believes that XF-73 has the potential to be part of new treatment regimens that could help reduce the incidence of such bacterial infections by reducing the bacterial carriage quickly in COVID- 19-infected patients in the ICU. Equally relevant is an increased interest in the anti-infective sector, driven by the coronavirus but also with a crossover into treatment of bacterial infections and issue of antimicrobial resistance (AMR). Lessons learned or to be learned from nations’ pandemic preparedness, or in some cases lack thereof, will hopefully drive governments to ensure that the pharmaceutical industry and innovators are sufficiently incentivised to develop new anti-bacterials that address the superbugs and AMR. If large pharma is unwilling to invest in this area, it will ultimately fall to governments to do so. The panic caused by the SARS-CoV-2 pandemic will pale into insignificance if there are microbes that became resistant to all current antibiotics! Destiny offers the possibility with its XF platform of generating novel antibiotics that have an alternative mechanism of action to existing antibiotics and where there is no evidence to date of resistance developing against the XF platform.” "
hedgehog 100: 15/07/2020 07:00 RNSNON Destiny Pharma PLC Destiny Pharma notes launch of AMR Action Fund Destiny Pharma notes launch of $1 billion pharma-backed fund to develop new anti-infectives Fund underlines the market urgency for the development of novel safe and effective antimicrobials such as Destiny Pharma's lead asset, XF-73 XF-73 is currently in a phase 2b clinical study investigating its use in the prevention of post-surgical bacterial infections Brighton, United Kingdom - 15 July 2020 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), notes the launch of the AMR Action Fund to provide financial resources and technical support to help biotechnology companies bring novel anti-infective drugs to patients. These are needed urgently to fight the worldwide rise in antimicrobial-resistant superbugs. Over 20 leading pharmaceutical companies have pledged to invest a total of $1 billion in a fund to help bridge innovative candidates in the pipeline through the later stages of drug development and to work with governments to ensure there is a sustainable pipeline of new antibiotics that address AMR. The pharmaceutical industry, in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust, have joined forces to design the fund, which aims to bring between two and four new antibiotics to market by 2030. For more information visit hxxps:// . This new pharma-backed fund underlines the urgency for the development of novel safe and effective antimicrobials such as Destiny Pharma's lead asset, XF-73. XF-73 is currently in a phase 2b clinical study investigating its use in the prevention of post-surgical bacterial infections, including the superbug MRSA. Neil Clark, Chief Executive Officer of Destiny Pharma, commented: "We welcome this significant new fund supporting novel drug development addressing AMR. The world needs new anti-infective drugs and Destiny Pharma is one of the leading biotechnology companies dedicated to addressing this global clinical need. The new pharma backed fund is the latest in a series of new initiatives from regulators, governments and healthcare investors to support innovation that addresses AMR."
johnniew156: Literally a couple of minutes after my posting, B'berg popped up with a delayed trade on the QR page. 1.4m shares were crossed at 35p at 15:56.18 yesterday, so yesterday's volume has been adjusted to 1,438,389 shares. In my view it would be extremely coinciental if this sale (of 1.4m shares) was not the balance of the 1.521943m Garraway stake that I am guessing was placed directly into market at least initially & ended up smashing the share price yesterday.
Destiny Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200921 04:10:17